Quantbot Technologies LP Increases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Quantbot Technologies LP increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 389.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,705 shares of the medical research company’s stock after purchasing an additional 12,495 shares during the quarter. Quantbot Technologies LP’s holdings in IQVIA were worth $3,722,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Versant Capital Management Inc boosted its stake in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in IQVIA during the 2nd quarter valued at approximately $27,000. Capital Performance Advisors LLP acquired a new position in IQVIA during the 3rd quarter worth $27,000. Park Place Capital Corp acquired a new position in IQVIA during the 3rd quarter worth $28,000. Finally, Itau Unibanco Holding S.A. acquired a new position in IQVIA during the 2nd quarter worth $29,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft reduced their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Robert W. Baird reduced their price target on IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Truist Financial cut their price objective on IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a report on Monday, November 4th. Evercore ISI cut their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, TD Cowen cut their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Trading Down 1.4 %

Shares of IQV opened at $201.24 on Wednesday. The stock has a fifty day moving average price of $221.18 and a two-hundred day moving average price of $226.75. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a market cap of $36.53 billion, a price-to-earnings ratio of 26.41, a PEG ratio of 2.10 and a beta of 1.51.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.